

## Prior Authorization Request Form PCSK-9 Inhibitors

Standard  Urgent

Reconsideration/Appeal

### Patient Information

Patient Name: \_\_\_\_\_ DOB (mm/dd/yyyy): \_\_\_\_\_ Gender: \_\_\_\_\_  
Address: \_\_\_\_\_ City: \_\_\_\_\_ State & Zip: \_\_\_\_\_  
Cardholder ID: \_\_\_\_\_ Group #: \_\_\_\_\_ Relationship Code: \_\_\_\_\_  
Phone Number: \_\_\_\_\_ Email address: \_\_\_\_\_

### Prescriber Information

Prescriber Name: \_\_\_\_\_ Specialty: \_\_\_\_\_ NPI: \_\_\_\_\_  
Address: \_\_\_\_\_ City: \_\_\_\_\_ State & Zip: \_\_\_\_\_  
Office Contact: \_\_\_\_\_ Phone Number: \_\_\_\_\_ Fax Number: \_\_\_\_\_

### Medication Information

Drug Name: \_\_\_\_\_ Strength: \_\_\_\_\_ Quantity: \_\_\_\_\_  
Directions: \_\_\_\_\_ Day Supply: \_\_\_\_\_  
Indicate Request Type:  New Start  Renewal      Therapy Start Date (if applicable): \_\_\_\_\_  
Diagnosis: \_\_\_\_\_ ICD 10 Code: \_\_\_\_\_

### Prior Authorization Request Information

**\*\*Supporting documentation (i.e., chart notes, labs, etc.) must be attached to avoid processing delays\*\***

For initial requests:

1. Please select the patient's diagnosis:

- Homozygous familial hypercholesterolemia (HoFH) – must select one of the following:  N/A
  - Genetic variant at the LDLR, Apo-B, PCSK9, or 1/LDLRAP1 gene
  - History of cutaneous or tendon xanthomas before age of 10 years
- Heterozygous familial hypercholesterolemia (HeFH) – must select one of the following:  N/A
  - Genetic variant at the LDLR, Apo-B, PCSK9, or 1/LDLRAP1 gene
  - History of myocardial infarction in first-degree relative < 60 years or second-degree relative < 50 years
  - History of HeFH, HoFH, tendinous xanthomata, and/or arcus cornealis in first or second-degree relative
- Primary Hyperlipidemia – must select one of the following:  N/A
  - Familial hypercholesterolemia     Familial hypertriglyceridemia
- Diagnosis of Atherosclerotic Cardiovascular Disease (ASCVD) – must select one of the following:  N/A
  - Acute coronary syndrome       History of myocardial infarction       Stable or unstable angina
  - Stroke       Coronary/Peripheral artery disease       Transient ischemic attack
  - Peripheral artery disease       Other: \_\_\_\_\_
- Other: \_\_\_\_\_

Please continue to the next page.

Patient Name: _____	DOB: _____
---------------------	------------

- |                                                                                                                                                                                |                                                          |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------|
| 2. Will the requested agent be used in combination with be used concomitantly with another PCSK-9 inhibitor?                                                                   | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| 3. Does the patient have any FDA contraindications to the requested agent?                                                                                                     | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| 4. Will the patient be taking any other medications in combination with the requested agent for the treatment of this diagnosis? If yes, please list: _____                    | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| 5. Has the patient had a lipid panel completed within the past 3 months? Must provide results.                                                                                 | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| 6. Has the patient had an inadequate clinical response to at least a 12-week supply of TWO statins at maximally tolerated doses? If yes, please list below.                    | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| 7. Has the patient had an intolerance or contraindication to at least TWO statins at maximally tolerated doses? Please submit documentation                                    | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| <input type="checkbox"/> Muscle systems with CK elevations >10x ULN <input type="checkbox"/> Myalgia <input type="checkbox"/> Myositis <input type="checkbox"/> Rhabdomyolysis |                                                          |

Drug Name/Strength:	Start Date:	End Date:	Outcome:

- For Renewal Requests:**
- |                                                                                                                          |                                                          |
|--------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------|
| 1. Has the patient had a positive clinical response to therapy? Must submit lipid results from within the past 3 months. | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| 2. Will the requested agent be used in combination with be used concomitantly with another PCSK-9 inhibitor?             | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| 3. Does the patient have any FDA contraindications to the requested agent?                                               | <input type="checkbox"/> Yes <input type="checkbox"/> No |

Prescriber Signature: _____	Date: _____
Authorized Agent's Name: _____	
<p><b>Please fax this request to 602-585-0588 or our secure email at <a href="mailto:care@disclosedrx.com">care@disclosedrx.com</a></b></p> <p><b>Mail Requests to: DisclosedRx Clinical Team</b></p> <p><b>PO Box 701 Washington, IN 47501</b></p>	

<b>Additional Comments/Notes:</b>